Bristol-Myers Squibb
This article was originally published in The Gray Sheet
Executive Summary
Board authorizes a $2 bil. increase in the company's common stock repurchase program, raising the previously approved spending limit of $6 bil. to $8 bil., effective immediately. Since 1994, BMS has repurchased approximately 79 mil. shares of its stock at an aggregate cost of $4 bil